# Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia

Study · id `cardio:ct-nct05410860` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05410860](<https://clinicaltrials.gov/study/NCT05410860>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05410860

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 500 participants.

## Technical summary

Registry record NCT05410860. Randomized; triple masking; primary purpose treatment. Start 2022-06-30 (actual); primary completion 2024-08-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 500 participants (enrolled count; ClinicalTrials.gov record NCT05410860, source copy `cardio:ctgov-nct05410860-2026-11-02`, retrieved 2026-11-18)
- Started: 2022-06-30 (actual) (ClinicalTrials.gov record NCT05410860, source copy `cardio:ctgov-nct05410860-2026-11-02`, retrieved 2026-11-18)
- Primary completion: 2024-08-02 (actual) (ClinicalTrials.gov record NCT05410860, source copy `cardio:ctgov-nct05410860-2026-11-02`, retrieved 2026-11-18)
- Completion: 2024-12-10 (actual) (ClinicalTrials.gov record NCT05410860, source copy `cardio:ctgov-nct05410860-2026-11-02`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT05410860, source copy `cardio:ctgov-nct05410860-2026-11-02`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05410860-2026-11-02`, retrieved 2026-11-18)

## The registry's words

- Brief title: Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
- Condition: Tachycardia, Supraventricular
- Condition: Paroxysmal Supraventricular Tachycardia
- Intervention (Drug): Etripamil NS 70 mg
- Intervention (Drug): Placebo
- Lead sponsor: Corxel Pharmaceuticals
- Lead sponsor class: INDUSTRY
- Collaborator: Milestone Pharmaceuticals Inc.
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Supraventricular tachycardia (`cardio:supraventricular-tachycardia`)
- Registry lists this organization as the lead sponsor: Corxel Pharmaceuticals (`cardio:org-corxel-pharmaceuticals`)
- Registry lists this organization as a collaborator: Milestone Pharmaceuticals Inc. (`cardio:org-milestone-pharmaceuticals-inc`)

## Provenance

Content hash: 59ba39b70df69698d3686afa959940aefd128935399e82115df76988c42b530b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
